Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...
A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
Everyday Health on MSN
Chronic inflammatory demyelinating polyneuropathy (CIDP) treatments
Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.
Artificial intelligence to speed diagnosis, switching complement therapies, ravulizumab during pregnancy, and iptacopan outcomes are some of the PNH advances from ASH 2025.
Medical University of South Carolina scientists have uncovered a link between the innate immune system and cognitive problems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback